Thermo Fisher Scientific to Announce Q4 Earnings on January 29
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Earnings Announcement: Thermo Fisher Scientific is set to release its Q4 2023 earnings on January 29 before market open, with consensus EPS estimated at $6.45, reflecting a 5.7% year-over-year increase, and revenue expected at $11.89 billion, up 4.3%, indicating solid growth potential in the market.
- Historical Performance: Over the past two years, Thermo Fisher has exceeded EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's strong capabilities in financial management and market forecasting.
- Estimate Revisions: In the last three months, EPS estimates have seen one upward revision and five downward adjustments, while revenue estimates experienced one upward revision and two downward changes, reflecting market uncertainty regarding the company's future performance.
- Strategic Partnership: Thermo Fisher's collaboration with Nvidia to leverage AI for improving lab workflows highlights the company's ongoing commitment to technological innovation, aiming to enhance operational efficiency and competitive positioning in the market.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 623.910
Low
580.00
Averages
658.89
High
750.00
Current: 623.910
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
